Intravenous versus oral iron for treatment of iron deficiency in non-hemodialysis-dependent patients with chronic kidney disease

American Journal of Health-System Pharmacy

Volumn 69, Issue 14, 2012, Pages 1206-1211

  Liles, Anne Marie ^a  

^a AUBURN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANEMIC AGENT; FERRITIN; HEMOGLOBIN; IRON; PHOSPHATE BINDING AGENT; TRANSFERRIN;

ANEMIA; BLOOD SAMPLING; CHRONIC KIDNEY DISEASE; FERRITIN BLOOD LEVEL; GASTROINTESTINAL ABSORPTION; HEMODIALYSIS; HEMOGLOBIN BLOOD LEVEL; HUMAN; INFLAMMATION; IRON ABSORPTION; IRON DEFICIENCY; IRON INTAKE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TRANSFERRIN BLOOD LEVEL;

EID: 84863971685     PISSN: 10792082     EISSN: 15352900     Source Type: Journal    
DOI: 10.2146/ajhp110231     Document Type: Review

References (20)

1. National Kidney Foundation. KDOQI clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease. Am J Kidney Dis. 2006; 47(suppl 3):S11-145.
2. McClellan W, Aronoff SL, Bolton WK et al. The prevalence of anemia in patients with chronic kidney disease. Curr Med Res Opin. 2004; 20:1501-10. (Pubitemid 39361354)
3. Fishbane S. Iron management in nondialysis-dependent CKD. Am J Kidney Dis. 2007; 49:736-43. (Pubitemid 46802932)
4. Fishbane S, Pollack S, Feldman HI et al. Iron indices in chronic kidney disease in the National Health and Nutritional Examination Survey 1988-2004. Clin J Am Soc Nephrol. 2009; 4:57-61.
5. Gotloib L, Silverberg D, Fudin R et al. Iron deficiency is a common cause of anemia in chronic kidney disease and can often be corrected with intravenous iron. J Nephrol. 2006; 19:161-7. (Pubitemid 44420105)
6. European Renal Association-European Dialysis and Transplant Association. Revised European best practice guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant. 2004; 19(suppl 2):ii1-47.
7. MacDougall IC, Tucker B, Thompson J et al. A randomized controlled study of iron supplementation in patients treated with erythropoietin. Kidney Int. 1996; 50:1694-9. (Pubitemid 26364277)
8. Markowitz GS, Kahn GA, Feingold RE et al. An evaluation of the effectiveness of oral iron therapy in hemodialysis patients receiving recombinant human erythropoietin. Clin Nephrol. 1997; 48:34-40. (Pubitemid 27312084)
9. Zaritsky J, Young B, Wang H et al. Hepcidin-a potential novel biomarker for iron status in chronic kidney disease. Clin J Am Soc Nephrol. 2009; 4:1051-6.
10. Hayat A. Safety issues with intravenous iron products in the management of anemia in chronic kidney disease. Clin Med Res. 2008; 6:93-102.
11. Stoves J, Inglis H, Newstead CG. A randomized study of oral vs intravenous iron supplementation in patients with progressive renal insufficiency treated with erythropoietin. Nephrol Dial Transplant. 2001; 16:967-74. (Pubitemid 32440369)
12. Ford ES. Body mass index, diabetes, and C-reactive protein among U.S. adults. Diabetes Care. 1999; 22:1971-7. (Pubitemid 30433974)
13. Albitar S, Genin R, Fen-Chong M et al. High dose enalapril impairs the response to erythropoietin treatment in haemodialysis patients. Nephrol Dial Transplant. 1998; 13:1206-10. (Pubitemid 28227199)
14. Cruz DN, Perazella MA, Abu-Alfa AK et al. Angiotensin-converting enzyme inhibitor therapy in chronic hemodialysis patients: any evidence of erythropoietin resistance? Am J Kidney Dis. 1996; 28:535-40. (Pubitemid 26337592)
15. Ertürk S, Ateş K, Duman N et al. Unresponsiveness to recombinant human erythropoietin in hemodialysis patients: possible implications of angiotensin-converting enzyme inhibitors. Nephrol Dial Transplant. 1996; 11:396-7. (Pubitemid 26063100)
16. Aggarwal HK, Nand N, Singh S et al. Comparison of oral versus intravenous iron therapy in predialysis patients of chronic renal failure receiving recombinant human erythropoietin. J Assoc Physicians India. 2003; 51:170-4. (Pubitemid 44227894)
17. Charytan C, Qunibi W, Bailie GR. Comparison of intravenous iron sucrose to oral iron in the treatment of anemic patients with chronic kidney disease not on dialysis. Nephron Clin Pract. 2005; 100:55-62.
18. Van Wyck DB, Roppolo M, Martinez CO et al. A randomized, controlled trial comparing iv iron sucrose to oral iron in anemic patients with nondialysis-dependent CKD. Kidney Int. 2005; 68:2846-56. (Pubitemid 43251032)
19. Spinowitz BS, Kausz AT, Baptista J et al. Ferumoxytol for treating iron deficiency anemia in CKD. J Am Soc Nephrol. 2008; 19:1599-605.
20. Qunibi WY, Martinez C, Smith M et al. A randomized controlled trial comparing intravenous ferric carboxymaltose with oral iron for treatment of iron deficiency anaemia of non-dialysis-dependent chronic kidney disease patients. Nephrol Dial Transplant. 2010; 26:1599-607.